Organon to buy therapy developer Dermavant for up to $1.2 billion
18/09/2024 12:37
Sept 18 (Reuters) - Healthcare company Organon OGN.N said on Wednesday it has agreed to acquire Dermavant, a Roivant ROIV.O company, for up to $1.2 billion. (Reporting by Sneha S K; Editing by Vijay Kishore) ((Sneha.SK@thomsonreuters.com;))
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple